skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Farletuzumab (Code C61503)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Farletuzumab

Definition: A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen that is overexpressed on many epithelial-derived cancer cells. Upon binding to the GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing cells resulting in cell lysis.

Display Name: Farletuzumab

Label: Farletuzumab

NCI Thesaurus Code: C61503 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2700602  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Farletuzumab
FARLETUZUMAB
MORAb-003

External Source Codes: 
CAS Registry Number 896723-44-7 (see NLM ChemIDplus info)
FDA UNII Code 2O09BG0OWA
PDQ Closed Trial Search ID 486728
PDQ Open Trial Search ID 486728 (check for NCI PDQ open clinical trial info)
UMLS CUI C2700602

Other Properties:
     Name Value (qualifiers indented underneath)
code C61503
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-GP-3_Monoclonal_Antibody
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61503

Mainbox Bottom